To direct the Secretary of Veterans Affairs to carry out a pilot program to expand access to virtual-based opioid treatment for covered veterans, and for other purposes.

What happened: Representative Deborah K. Ross (D-NC-2) introduced HR10037 on August 3, 2026. The bill was referred to the House Committee on Veterans' Affairs. It has two original cosponsors — Rep. Davis (D-NC-1) and Rep. Miller (R-WV-1) — showing modest bipartisan support. The bill's stated purpose is to direct the VA to carry out a pilot program expanding access to virtual-based opioid treatment for covered veterans. Action history shows only introduction and referral; no hearings or markups have occurred.

Money trail: This bill does not authorize any specific dollar amount. It is a programmatic directive — it orders the VA to design and implement a pilot, but actual funding would require a separate appropriation. The cost is likely small, probably under $10 million, and would be absorbed within existing VA telehealth budgets if enacted. Until the bill moves out of committee and a companion bill appears in the Senate, no money is committed.

Structural winners: If the pilot becomes law, the VA will need a telehealth platform to deliver virtual opioid treatment (counseling and medication-assisted therapy). Two publicly traded telehealth companies are positioned: Teladoc ($TDOC) — the largest pure-play virtual care provider with an existing opioid treatment program — and Amwell ($AMWL) — which already has VA contracts and a platform integrated with VA's EHR. Both would compete for what is likely a modest contract. Given the pilot's small scale, the revenue impact on either company is negligible (less than 0.5% of revenue). The bill's passage probability is low: early-stage authorization bills without funding rarely advance, and the 119th Congress has a split or narrow majority. The main investment takeaway is not the dollar amount but the signal: Congress continues to support telehealth and opioid treatment integration — a long-term tailwind for the sector, but not a near-term catalyst.

Timeline: The bill faces a multi-step path: committee markup, House floor vote, Senate introduction and passage, and then appropriations. Given the referral date and early stage, movement within the next 6-12 months is unlikely. Investors should monitor for committee hearings and a companion bill in the Senate.